Shouyao Holdings 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


12»
  • ||||||||||  Retrospective data, Review, Journal, Metastases:  Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-na (Pubmed Central) -  Sep 12, 2024   
    Eight studies, involving 1,477 Asian patients and seven treatments (crizotinib, alectinib, brigatinib, ensartinib, envonalkib, iruplinalkib, and lorlatinib), were included in the NMA. Next-generation ALK inhibitors had better efficacy than crizotinib in the treatment of Asian patients with ALK inhibitor-na
  • ||||||||||  conteltinib (SY-707) / Centaurus Biopharma, Shouyao Holdings, SY-5933 / Shouyao Holdings
    Targeting FAK to improve the therapy of KRAS G12C mutant cancers (Section 24) -  Mar 5, 2024 - Abstract #AACR2024AACR_4014;    
    In conclusion, our results demonstrate that CT-707 has the potential to enhance the efficacy of SY-5933 by suppressing adaptive FAK activation under KRAS G12C inhibition. This provides a rationale for an innovative combination therapy to improve outcomes in patients with KRAS G12C mutated cancers.
  • ||||||||||  Review, Journal:  Roles and inhibitors of FAK in cancer: current advances and future directions. (Pubmed Central) -  Feb 27, 2024   
    This review aims to clarify FAK's role in cancer, offering a comprehensive overview of the current status and future prospects of FAK-targeted therapy and combination approaches. The goal is to provide valuable insights for advancing anti-cancer treatment strategies.
  • ||||||||||  ficonalkib (SY-3505) / Shouyao Holdings
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=38, Recruiting, 
    The goal is to provide valuable insights for advancing anti-cancer treatment strategies. Trial completion date: Dec 2025 --> May 2026 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Jun 2025 --> Dec 2025
  • ||||||||||  SY-4835 / Shouyao Holdings
    Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=40, Recruiting, 
    Trial completion date: Dec 2025 --> May 2026 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Jun 2025 --> Dec 2025 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Jun 2024
  • ||||||||||  SY-4798 / Shouyao Holdings
    Trial completion date, Trial primary completion date, Metastases:  A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor (clinicaltrials.gov) -  May 11, 2023   
    P1,  N=80, Recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Jun 2024 Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  SY-4835 / Shouyao Holdings
    Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 12, 2023   
    P1,  N=40, Recruiting, 
    Trial primary completion date: Mar 2023 --> Jan 2025 Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Nov 2023
  • ||||||||||  SY-5007 / Shouyao Holdings
    Phase classification, Enrollment change, Trial completion date, Metastases:  Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (clinicaltrials.gov) -  Feb 27, 2023   
    P1/2,  N=200, Recruiting, 
    Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Nov 2023 Phase classification: P1 --> P1/2 | N=80 --> 200 | Trial completion date: Jun 2023 --> Feb 2025
  • ||||||||||  ficonalkib (SY-3505) / Shouyao Holdings
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Feb 14, 2023   
    P1/2,  N=150, Recruiting, 
    Phase classification: P1 --> P1/2 | N=80 --> 200 | Trial completion date: Jun 2023 --> Feb 2025 Phase classification: P1 --> P1/2 | N=70 --> 150 | Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Nov 2022 --> Apr 2024
  • ||||||||||  ficonalkib (SY-3505) / Shouyao Holdings
    Trial primary completion date, Metastases:  Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Oct 26, 2022   
    P1,  N=70, Recruiting, 
    The recommended phase 2 dose was determined to be 600 mg QD for ALK TKI-naïve patients and 300 mg bis in die (BID) for patients who received crizotinib previously. Trial primary completion date: Jun 2022 --> Nov 2022
  • ||||||||||  conteltinib (CT-707) / Centaurus Biopharma, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling. (Pubmed Central) -  Apr 27, 2022   
    TQ-B3139 was well-tolerated and exhibited promising anti-tumor activities in patients with ALK and ROS1 positive advanced NSCLC. Overall, this study not only favors the development of this novel multi-kinase inhibitor CT-707 as a therapeutic agent against HCC, but also provides a potential strategy to overcome the hypoxia-mediated resistance to sorafenib in HCC patients.
  • ||||||||||  SY-5007 / Shouyao Holdings
    Trial primary completion date, Metastases:  Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (clinicaltrials.gov) -  Apr 7, 2022   
    P1,  N=80, Recruiting, 
    Overall, this study not only favors the development of this novel multi-kinase inhibitor CT-707 as a therapeutic agent against HCC, but also provides a potential strategy to overcome the hypoxia-mediated resistance to sorafenib in HCC patients. Trial primary completion date: Mar 2022 --> Mar 2023
  • ||||||||||  ficonalkib (SY-3505) / Shouyao Holdings
    Trial completion date, Trial primary completion date, Metastases:  Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Mar 17, 2022   
    P1,  N=70, Recruiting, 
    Trial primary completion date: Mar 2022 --> Mar 2023 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
  • ||||||||||  Anluoqing (envonalkib) / Sino Biopharm, Shouyao Holdings
    Enrollment open, Trial primary completion date:  Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules (clinicaltrials.gov) -  Apr 1, 2021   
    P1,  N=12, Recruiting, 
    The dose-expansion phase of this study is ongoing. Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2021 --> Mar 2022
  • ||||||||||  Anluoqing (envonalkib) / Sino Biopharm, Shouyao Holdings
    Enrollment open, Metastases:  A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Sep 10, 2020   
    P2,  N=71, Recruiting, 
    These findings indicate that CT-707 may be a promising therapeutic agent against crizotinib-resistance in NSCLC. Not yet recruiting --> Recruiting
  • ||||||||||  Anluoqing (envonalkib) / Sino Biopharm, Shouyao Holdings
    Enrollment open, Trial initiation date, Metastases:  A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics (clinicaltrials.gov) -  Sep 18, 2017   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Jul 2017